ImmVirX
Latest round
- Series B
Last raised
- Jun 2023
Total raised
- $36M
Investors
- 6
About ImmVirX
Based in New Lambton Heights, Australia, and founded in 2019, ImmVirX Pty Ltd operates as a developer of oncolytic viral immunotherapy that utilizes RNA viruses to kill the cancer cells and trigger an immune response from the body to stop tumors from developing. The company was co-founded by Dr. Malcolm McColl and Prof. ImmVirX develops proprietary oncolytic RNA viruses which have been bio-selected to have potency and the ability to be replicated to kill target tumor cells and not healthy cells, resulting in the potential generation of specific and adaptive immune responses against cancer.
Who invested in ImmVirX
6 investors across 3 rounds
See all investors in ImmVirX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ImmVirX
Who invested in ImmVirX?
ImmVirX has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ImmVirX raised?
ImmVirX has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did ImmVirX last raise money?
ImmVirX's most recent round on record is a Series B, in Jun 2023.
What does ImmVirX do?
Based in New Lambton Heights, Australia, and founded in 2019, ImmVirX Pty Ltd operates as a developer of oncolytic viral immunotherapy that utilizes RNA viruses to kill the cancer cells and trigger an immune response from the body to stop tumors from developing.
Where is ImmVirX headquartered?
ImmVirX is headquartered in Australia.
Which VCs invest in companies like ImmVirX?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Movac back biotechnology companies at ImmVirX's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like ImmVirX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.